Select Page
Club de lecture l'Actuel

For 30 years, the Clinique médicale l’Actuel, under the medical direction of Dr. Réjean Thomas, has been bringing together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.

Simplification of antiretroviral treatment

With Dr. Réjean Thomas and Prof. Christine Katlama


After clicking PLAY, click on the lower bar’s subtitles icon [CC] for english subtitles.


  • Should we treat all patients the same way?

  • The issue of toxicity in treatment over a very long term

  • Fewer molecules for equivalent efficacy?

  • Patients increasingly interested in simplifying their treatment

This activity is supported by an educational grant from:

ViiV Healthcare



Simplifying antiretroviral treatment

Thanks to the increasing efficacy of antiretroviral drugs – more potent, more robust and better tolerated molecules – PLHIV have a life expectancy nearly the same as uninfected people, and today everyone agrees on recommending early treatment of HIV for all infected persons. In this context of providing long-term or very long-term care, reducing combinations to reduce the toxicity of treatments becomes a clinical issue.

To date, in certain circumstances where treatment is provided early, where the viral load has been controlled for several years or the reservoir is low, experiments with reducing treatment have proven successful; treatment efficacy remains the same. According to Prof. Katlama, we are entering a “green era” in treatment, where we need to adopt a more eco-friendly and “economical” approach to go easier on the bodies of PLHIV, and bring into the field of HIV the concept of differentiated treatments for the same disease, depending on the condition and reality of each patient.

There is not yet consensus regarding this new practice.

Réjean Thomas, MD, Dhc

Réjean Thomas, MD, Dhc


CEO – Founder
Clinique médicale l’Actuel: Centre of Excellence HIV–STI–Hepatitis
Affiliated with the Centre hospitalier de l’Université de Montréal (CHUM)
Québec, Canada

Christine Katlama, MD

Christine Katlama, MD


Department of Infectious and Tropical Diseases
Pitié-La Salpêtrière Hospital
Paris, France



You must be logged in to view the complete program
ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Réjean Thomas, MD, Dhc has a financial interest/relationship or affiliation with:
Advisory boards: AbbVie, Bristol-Myers Squibb Janssen, Gilead, Merck, ViiV Healthcare
Prof. Christine Katlama, MD, has a financial interest/relationship or affiliation with:

Disclosure of Unlabeled Use The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.